Cetera Investment Advisers Grows Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Cetera Investment Advisers raised its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 169.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 356,222 shares of the company's stock after acquiring an additional 224,222 shares during the quarter. Cetera Investment Advisers owned approximately 0.13% of Autolus Therapeutics worth $837,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Autolus Therapeutics in the 4th quarter valued at about $26,000. Barclays PLC grew its position in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter valued at approximately $35,000. Arkadios Wealth Advisors purchased a new position in Autolus Therapeutics during the fourth quarter worth approximately $47,000. Finally, Daiwa Securities Group Inc. boosted its stake in Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after buying an additional 8,479 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AUTL. Truist Financial cut their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 10th. Finally, Wells Fargo & Company reduced their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $9.32.

Autolus Therapeutics Trading Up 6.1%

AUTL traded up $0.10 on Thursday, hitting $1.75. The company had a trading volume of 2,296,789 shares, compared to its average volume of 1,504,438. The company's fifty day moving average price is $1.41 and its 200 day moving average price is $2.02. Autolus Therapeutics plc has a 1 year low of $1.11 and a 1 year high of $5.00. The firm has a market cap of $465.75 million, a P/E ratio of -1.45 and a beta of 1.77.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. On average, analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.